0.44
price up icon0.40%   0.00175
 
loading

Equillium Inc Aktie (EQ) Neueste Nachrichten

pulisher
Apr 25, 2025

FDA declines itolizumab accelerated approval, says Equillium - The Pharma Letter

Apr 25, 2025
pulisher
Apr 24, 2025

Equillium shares fall following FDA feedback By Investing.com - Investing.com India

Apr 24, 2025
pulisher
Apr 24, 2025

Equillium shares fall following FDA feedback - Investing.com Australia

Apr 24, 2025
pulisher
Apr 24, 2025

Equillium Announces Feedback from the U.S. Food and Drug Adminis - GuruFocus

Apr 24, 2025
pulisher
Apr 24, 2025

Equillium (EQ) Faces Setback as FDA Declines Accelerated Approva - GuruFocus

Apr 24, 2025
pulisher
Apr 24, 2025

FDA declines Equillium’s itolizumab accelerated approval By Investing.com - Investing.com Canada

Apr 24, 2025
pulisher
Apr 24, 2025

Equillium (EQ) Faces FDA Setback for Itolizumab in Graft-versus-Host Disease Treatment | EQ Stock News - GuruFocus

Apr 24, 2025
pulisher
Apr 24, 2025

FDA declines Equillium’s itolizumab accelerated approval - Investing.com

Apr 24, 2025
pulisher
Apr 24, 2025

Equillium Announces Feedback from the U.S. Food and Drug Administration - Business Wire

Apr 24, 2025
pulisher
Apr 22, 2025

Equillium (NASDAQ:EQ) Shares Down 3.7% – Here’s Why - Defense World

Apr 22, 2025
pulisher
Apr 01, 2025

Equillium (EQ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance

Apr 01, 2025
pulisher
Mar 31, 2025

Revenues Working Against Equillium, Inc.'s (NASDAQ:EQ) Share Price Following 47% Dive - simplywall.st

Mar 31, 2025
pulisher
Mar 31, 2025

Leerink Partnrs Forecasts Equillium FY2029 Earnings - Defense World

Mar 31, 2025
pulisher
Mar 30, 2025

Leerink Partners Reaffirms “Market Perform” Rating for Equillium (NASDAQ:EQ) - Defense World

Mar 30, 2025
pulisher
Mar 30, 2025

Leerink Partnrs Downgrades Equillium (NASDAQ:EQ) to Hold - Defense World

Mar 30, 2025
pulisher
Mar 28, 2025

Leerink Partners Downgrades Equillium (LSE:0A4D) - Nasdaq

Mar 28, 2025
pulisher
Mar 28, 2025

Equillium stock tumbles on Phase 3 study results By Investing.com - Investing.com India

Mar 28, 2025
pulisher
Mar 28, 2025

Equillium stock tumbles on Phase 3 study results - Investing.com

Mar 28, 2025
pulisher
Mar 28, 2025

Leerink Partners Downgrades Equillium to Market Perform From Outperform, Adjusts Price Target to $1 From $3 - MarketScreener

Mar 28, 2025
pulisher
Mar 28, 2025

Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease - BioSpace

Mar 28, 2025
pulisher
Mar 27, 2025

Equillium Reports 2024 Financials and Clinical Milestones - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium (EQ) Surprises with Smaller Q4 Loss Amid Revenue Dip - GuruFocus

Mar 27, 2025
pulisher
Mar 27, 2025

12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium stock hits 52-week low at $0.49 amid market challenges By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium Seeks Accelerated Approval For GVHD Drug Despite Primary Endpoint Miss - insights.citeline.com

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium reports mixed results in aGVHD study, seeks FDA fast track By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium pushes for breakthrough status despite missing primary endpoint - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

Gold Gains Over 1%; TD SYNNEX Shares Plunge After Downbeat Results - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium stock hits 52-week low at $0.49 amid market challenges - Investing.com Australia

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium fails to improve complete response in GVHD treatment study - Seeking Alpha

Mar 27, 2025
pulisher
Mar 27, 2025

Nasdaq Down Over 100 Points; US Initial Jobless Claims Fall - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium drug fails main trial goal but shows longer-term promise - The Pharma Letter

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium, Inc. Announces Results of the Phase 3 Equator Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium reports mixed results in aGVHD study, seeks FDA fast track - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium Reports Phase 3 Results Of Itolizumab For Acute Graft-Versus-Host Disease - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights - Joplin Globe

Mar 27, 2025
pulisher
Mar 27, 2025

Breakthrough GVHD Treatment: New Drug Extends Response Duration by 4.7x in Phase 3 Trial - Stock Titan

Mar 27, 2025
pulisher
Mar 17, 2025

Equillium (EQ) to Release Quarterly Earnings on Monday - Defense World

Mar 17, 2025
pulisher
Mar 14, 2025

Are Medical Stocks Lagging Aveanna Healthcare (AVAH) This Year? - Yahoo Finance

Mar 14, 2025
pulisher
Mar 07, 2025

Equillium Stock Price, Quotes and Forecasts - Benzinga

Mar 07, 2025
pulisher
Feb 28, 2025

SHAREHOLDER ALERT: Weiss Law Reminds EQ, IMGO, MTCR, and OPNT Shareholders About Its Ongoing Investigations - Marketscreener.com

Feb 28, 2025
pulisher
Feb 28, 2025

Equillium stock rallies 26% on itolizumab study data - MSN

Feb 28, 2025
pulisher
Feb 21, 2025

Here's Why Equillium (EQ) Is a Great 'Buy the Bottom' Stock Now - Zacks Investment Research

Feb 21, 2025
pulisher
Feb 12, 2025

Equillium, Inc.'s (NASDAQ:EQ) Price Is Right But Growth Is Lacking After Shares Rocket 27% - Simply Wall St

Feb 12, 2025
pulisher
Feb 11, 2025

Leerink Partnrs Forecasts Stronger Earnings for Equillium - Defense World

Feb 11, 2025
pulisher
Feb 10, 2025

Equillium (EQ) Upgraded to Buy: Here's What You Should Know - Yahoo Finance

Feb 10, 2025
pulisher
Feb 10, 2025

Equillium (EQ) Shows Fast-paced Momentum But Is Still a Bargain Stock - Nasdaq

Feb 10, 2025
pulisher
Feb 10, 2025

Healthy Upside Potential: Equillium Inc (EQ) - SETE News

Feb 10, 2025
$20.65
price up icon 0.63%
$70.47
price up icon 1.28%
$32.49
price up icon 0.64%
$23.90
price up icon 1.85%
$108.35
price up icon 3.89%
biotechnology ONC
$247.87
price up icon 1.21%
Kapitalisierung:     |  Volumen (24h):